Compare Ecopetrol SA (EC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Recursion Pharmaceuticals Inc — how do they compare? Ecopetrol SA trades at $15.78 (market cap $30.44B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.75B). The key difference: Ecopetrol SA is far larger — about 17.4× Recursion Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 4.06% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EC | RXRX | |
|---|---|---|
Market Cap | $30.44B | $1.75B |
Sector | Energy | Health |
52-Week High | $16.58 | $6.79 |
52-Week Low | $8.29 | $2.84 |
Enterprise Value | $58.23B | $1.17B |
Dividend Yield | 4.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $15.93, down 1.42% with mixed technical signals showing bullish moving averages but bearish oscillators. The company maintains solid profitability with 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6B in 2022 to $119.7B in 2025. Recent developments include a collective bargaining agreement with workers and upcoming Q2 2026 earnings release on August 3, 2026.
While valuation appears reasonable with P/E of 11.39, declining revenue trends and recent earnings misses pose challenges. Analyst consensus is cautious with 54.55% hold rating and $14.63 price target below current levels. Key risks include oil price volatility and execution challenges in a competitive energy sector.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
